Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: simlukafusp alfa, f19 131i, sibrotuzumab | 0.81 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 1 stopped | 0.80 |
| literature PubMed | 25 Parkinson's papers of 8,608 | 0.57 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 10091
Sealed predictions
- FAP in dopamine neurons, braak+0.49 (p 0.177) → +0.59 (p 0.096)receipt 10098
Swarm cases
receipt 10098: FAP in dopamine neurons, braak
- power
- full sample +0.50 (p 0.036, n 18), 95% CI +0.04 to +0.78. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.48 (p 0.046, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.50 (p 0.034, n 18). not the mix.
- skeptic
- leave-one-out range +0.45 to +0.69, sign flips 0; without severely affected donors +0.50 (p 0.036, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FAP in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts